Molecular markers of circulating melanoma cells

Pigment Cell Research

Volumn 20, Issue 2, 2007, Pages 80-91

  Medic, Sandra ^a   Pearce, Robert L ^a   Heenan, Peter J ^b   Ziman, Mel ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Circulating metastatic cells; Detection; Melanoma; Molecular markers

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; BUB1 RELATED PROTEIN; CD146 ANTIGEN; CD63 ANTIGEN; CYTOPLASMIC MELANOMA ASSOCIATED ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN CHITINASE LIKE PROTEIN; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ASSOCIATED CHONDROITIN SULFATE PROTEOGLYCAN; MELANOMA INHIBITORY ACTIVITY FACTOR; MELANOTRANSFERRIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; N ACETYLGALACTOSAMINYLTRANSFERASE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEIN P97; PROTEIN S100B; PROTEOGLYCAN; TRANSCRIPTION FACTOR PAX3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; DISEASE SEVERITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MELANOMA CELL; METASTASIS; MICROARRAY ANALYSIS; PERIPHERAL CIRCULATION; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

ANTIGENS, NEOPLASM; DISEASE PROGRESSION; HUMANS; MELANOMA; MUTATION; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; ONCOGENES; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947308611     PISSN: 08935785     EISSN: 16000749     Source Type: Journal    
DOI: 10.1111/j.1600-0749.2006.00356.x     Document Type: Review

References (104)

1. Albelda, S.M., Oliver, P.D., Romer, L.H., and Buck, C.A. (1990). Endocam: a novel endothelial cell-cell adhesion molecule. J. Cell Biol. 110, 1227-1237.
2. Aubin, F., Chtourou, M., Teyssier, J.R., Laubriet, A., Mougin, C.H., Blanc, D., and Humbert, P. (2000). The detection of tyrosinase mRNA in the peripheral blood of stage i melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res. 10, 113-118.
3. Balch, C.M., Buzaid, A.C., Soong, S.J. et al. (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648.
4. Battayani, Z., Grob, J.J., Xerri, L., Noe, C., Zarour, H., Houvaeneghel, G., Delpero, J.R., Birmbaum, D., Hassoun, J., and Bonerandi, J.J. (1995). Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol. 131, 443-447.
5. Bittner, M., Meltzer, P., Chen, Y. et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
6. Blake, J., and Ziman, M. (2003). Aberrant Pax3 and Pax7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol. Histoplathol. 18, 529-539.
7. Blake, J.A., and Ziman, M.R. (2005). Pax3 transcripts in melanoblast development. Dev. Growth Differ. 47, 627-635.
8. Bosserhof, A.K. (2005). Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res. 18, 411-416.
9. Bosserhoff, A.K., Kaufmann, M., Kaluza, B., Bartke, I., Zirngibl, H., Hein, R., Stolz, W., and Buettner, R. (1997). Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57, 3149-3153.
10. Bosserhoff, A.K., Dreau, D., Hein, R., Landthaler, M., Holder, W.D., and Buettner, R. (2001). Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results Cancer Res. 158, 158-168.
11. Bottoni, U., Izzo, P., Richetta, A., Mannooranparampil, T.J., Devirgiliis, V., Del Giudice, M., Reale, M.G., Frati, L., and Calvieri, S. (2003). S100 serum level: a tumour marker for metastatic melanoma. Melanoma Res. 13, 427-429.
12. Brossart, P., Schmier, J.W., Kruger, S., Willhauck, M., Scheibenbogen, C., Mohler, T., and Keilholz, U. (1995). A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 55, 4065-4068.
13. Brownbridge, G.G., Gold, J., Edward, M., and MacKie, R.M. (2001). Evaluation of the use of tyrosinase-specific and Melana/Mart-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br. J. Dermatol. 144, 279-287.
14. Carreira, S., Goodall, J., Aksan, I., LaRocca, S.A., Galiibert, M.-D., Denat, L., Larue, L., and Goding, C.R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433, 764-769
15. Carreira, S., Goodall, J., Denat, L., Larue, L., Rodrigúez, M., Nuciforo, P., Hoek, K., Testori, A, and Goding, C.R. (in press). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. (in press).
16. Chang, C.C., Campoli, M., Luo, W., Zhao, W., Zaenker, K.S., and Ferrone, S. (2004). Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann. N Y Acad. Sci. 1028, 340-350.
17. Curry, B.J., Myers, K., and Hersey, P. (1998). Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J. Clin. Oncol. 16, 1760-1769.
18. Curry, B.J., Myers, K., and Hersey, P. (1999). Mart-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J. Clin. Oncol. 17, 2562-2571.
19. Dadras, S.S., Paul, T., Bertoncini, J., Brown, L.F., Muzikansky, A., Jackson, D.G., Ellwanger, U., Garbe, C., Mihm, M.C., and Detmar, M. (2003). Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162, 1951-1960.
20. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the B-raf gene in human cancer. Nature 417, 949-954.
21. Deichmann, M., Benner, A., Bock, M., Jackel, A., Uhl, K., Waldmann, V., and Naher, H. (1999). S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on cancer stage iv melanoma. J. Clin. Oncol. 17, 1891-1896.
22. Deichmann, M., Thome, M., Benner, A., and Naher, H. (2004). B-RAF exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 66, 411-419.
23. Dooley, T.P., Reddy, S.P., Wilborn, T.W., and Davis, R.L. (2003). Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR. Biochem. Biophys. Res. Commun. 306, 1026-1036.
24. Du, J., Miller, A.J., Widlund, H.R., Horstmann, M.A., Ramaswamy, S., and Fisher, D.E. (2003). Mlana/mart1 and Silv/pMel17/gp100 are transcriptionally regulated by Mitf in melanocytes and melanoma. Am. J. Pathol. 163, 333-343.
25. Dutcher, J.P. (2003). The prognostic role of detection of circulating melanoma cells in the blood. J. Clin. Oncol. 21, 757-759.
26. Flaherty, K.T. (2004). New molecular targets in melanoma. Curr. Opin. Oncol. 16, 150-154.
27. Garbe, C., Leiter, U., Ellwanger, U., Blaheta, H.J., Meier, F., Rassner, G., and Schittek, B. (2003). Diagnostic value and prognostic significance of protein s-100beta, melanoma-inhibitory activity, and tyrosinase/Mart-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97, 1737-1745.
28. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122.
29. Ghossein, R.A., and Bhattacharya, S. (2000). Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur. J. Cancer 36, 1681-1694.
30. Ghossein, R.A., Coit, D., Brennan, M., Zhang, Z.F., Wang, Y., Bhattacharya, S., Houghton, A., and Rosai, J. (1998). Prognostic significance of peripheral blood and bone marrow tyrosinase messenger rna in malignant melanoma. Clin. Cancer Res. 4, 419-428.
31. Giacomini, P., Natali, P., and Ferrone, S. (1985). Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J. Immunol. 135, 696-702.
32. Gogas, H., Kefala, G., Bafaloukos, D., Frangia, K., Polyzos, A., Pectasides, D., Tsoutsos, D., Panagiotou, P., Ioannovich, J., and Loukopoulos, D. (2002). Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 87, 181-186.
33. Haass, N.K., Smalley, K., Li, L., and Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 18, 150-159.
34. Hamberg, A.P., Korse, C.M., Bonfrer, J.M., and de Gast, G.C. (2003). Serum S100b is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 13, 45-49.
35. Hanekom, G.S., Stubbings, H.M., Johnson, C.A., and Kidson, S.H. (1999). The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res. 9, 465-473.
36. Hauschild, A., Michaelsen, J., Brenner, W., Rudolph, P., Glaser, R., Henze, E., and Christophers, E. (1999). Prognostic significance of serum S100b detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 9, 155-161.
37. Hoek, K.S., Schlegel, N.C., Bradfford, P. et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no B-RAF signature. Pigment Cell Res. 19, 290-302.
38. Hoon, D.S., Wang, Y., Dale, P.S., Conrad, A.J., Schmid, P., Garrison, D., Kuo, C., Foshag, L.J., Nizze, A.J., and Morton, D.L. (1995). Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol. 13, 2109-2116.
39. Hoon, D.S., Bostick, P., Kuo, C., Okamoto, T., Wang, H.J., Elashoff, R., and Morton, D.L. (2000). Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60, 2253-2257.
40. Junker, N., Johansen, J.S., Andersen, C.B., and Kristjansen, P.E. (2005). Expression of ykl-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 48, 223-231.
41. Kashani-Sabet, M., Sagebiel, R.W., Ferreira, C.M., Nosrati, M., and Miller, J.R., III, (2002). Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J. Clin. Oncol. 20, 1826-1831.
42. Kashani-Sabet, M., Shaikh, L., Miller, J.R., III, Nosrati, M., Ferreira, C.M., Debs, R.J., and Sagebiel, R.W. (2004). Nf-kappa b in the vascular progression of melanoma. J. Clin. Oncol. 22, 617-623.
43. Keilholz, U., Goldin-Lang, P., Bechrakis, N.E., Max, N., Letsch, A., Schmittel, A., Scheibenbogen, C., Heufelder, K., Eggermont, A., and Thiel, E. (2004). Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase- polymerase chain reaction. Clin. Cancer Res. 10, 1605-1612.
44. Koyanagi, K., Kuo, C., Nakagawa, T., Mori, T., Ueno, H., Lorico, A.R., Jr., Wang, H.J., Hseuh, E., O'Day, S.J., and Hoon, D.S. (2005a). Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin. Chem. 51, 981-988.
45. Koyanagi, K., O'Day, S.J., Gonzalez, R. et al. (2005b). Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage iii melanoma: outcome prediction in a multicenter trial. J. Clin. Oncol. 23, 8057-8064.
46. Koyanagi, K., O'Day, S.J., Gonzalez, R. et al. (2006). Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin. Cancer Res. 12, 1137-1143.
47. Kunter, U., Buer, J., Probst, M. et al. (1996). Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J. Natl Cancer Inst. 88, 590-594.
48. Kunz, M., Ibrahim, S.M., Koczan, D., Scheid, S., Thiesen, H.J., and Gross, G. (2004). DNA microarray technology and its applications in dermatology. Exp. Dermatol. 13, 593-606.
49. Kuo, C., Hoon, D.S.B., Takeuchi, H., Turner, R., Wang, H.-J., Morton, D.L., and Taback, B. (2003). Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J. Clin. Oncol. 21, 3566-3572.
50. Kushimoto, T., Valencia, J.C., Costin, G.E., Toyofuku, K., Watabe, H., Yasumoto, K., Rouzaud, F., Vieira, W.D., and Hearing, V.J. (2003). The Seiji memorial lecture: the melanosome: an ideal model to study cellular differentiation. Pigment Cell Res. 16, 237-244.
51. Lewis, T.B., Robison, J.E., Bastien, R., Milash, B., Boucher, K., Samlowski, W.E., Leachman, S.A., Dirk Noyes, R., Wittwer, C.T., Perreard, L., et al. (2005). Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 104, 1678-1686.
52. Lin, L., Gerth, A.J., Peng, S.L. (2004). Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J. Exp. Med. 200, 115-122.
53. Lindblom, A., and Liljegren, A. (2000). Regular review: tumour markers in malignancies. BMJ 320, 424-427.
54. Loercher, AE, Tank, EM, Delston, RB, Harbour, JW. (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168, 35-40.
55. Malinda, K.M., Ponce, L., Kleinman, H.K., Shackelton, L.M., and Millis, A.J. (1999). Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell Res. 250, 168-173.
56. Martenson, E.D., Hansson, L.O., Nilsson, B., von Schoultz, E., Mansson Brahme, E., Ringborg, U., and Hansson, J. (2001). Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J. Clin. Oncol. 19, 824-831.
57. Matsuzaki, Y., Hashimoto, S., Fujita, T., Suzuki, T., Sakurai, T., Matsushima, K., and Kawakami, Y. (2005). Systematic identification of human melanoma antigens using serial analysis of gene expression (sage). J. Immunother. 28, 10-19.
58. Mellado, B., Colomer, D., Castel, T., Munoz, M., Carballo, E., Galan, M., Mascaro, J.M., Vives-Corrons, J.L., Grau, J.J., and Estape, J. (1996). Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol. 14, 2091-2097.
59. Mellado, B., Gutierrez, L., Castel, T., Colomer, D., Fontanillas, M., Castro, J., and Estape, J. (1999). Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 5, 1843-1848.
60. Mellado, B., Del Carmen Vela, M., Colomer, D. et al. (2002). Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol. 20, 4032-4039.
61. Mocellin, S., Del Fiore, P., Guarnieri, L., Scalerta, R., Foletto, M., Chiarion, V., Pilati, P., Nitti, D., Lise, M., and Rossi, C.R. (2004). Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int. J. Cancer 111, 741-745.
62. Molina, R., Navarro, J., Filella, X., Castel, T., and Ballesta, A.M. (2002). S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 23, 39-44.
63. Nigro, J.M., Misra, A., Zhang, L. et al. (2005). Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 65, 1678-1686.
64. Nishikawa, K.C., and Millis, A.J. (2003). Gp38k (chi3l1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. 287, 79-87.
65. Osella-Abate, S., Savoia, P., Quaglino, P., Fierro, M.T., Leporati, C., Ortoncelli, M., and Bernengo, M.G. (2003). Tyrosinase expression in the peripheral blood of stage iii melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br. J. Cancer 89, 1457-1462.
66. Palmieri, G., Strazzullo, M., Ascierto, P.A., Satriano, S.M., Daponte, A., and Castello, G. (1999). Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma cooperative group. J. Clin. Oncol. 17, 304-311.
67. Palmieri, G., Ascierto, P.A., Perrone, F. et al. (2003). Prognostic value of circulating melanoma cells detection by reverse transcriptase-polymerase chain reaction. J. Clin. Oncol. 21, 767-773.
68. Pantel, K., Cote, R.J., and Fodstad, O. (1999). Detection and clinical importance of micrometastatic disease. J. Natl Cancer Inst. 91, 1113-1124.
69. Patton, E.E., Widlund, H.R., Kutok, J.L. et al. (2005). B-raf mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254.
70. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of B-raf mutations in nevi. Nat. Genet. 33, 19-20.
71. Poser, I., and Bosserhoff, A.-K. (2004). Transcription factors involved in development and progression of malignant melanoma. Histol. Histopathol. 19, 173-188.
72. Proebstle, T.M., Jiang, W., Hogel, J., Keilholz, U., Weber, L., and Voit, C. (2000). Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer 82, 118-123.
73. Quaglino, P., Savoia, P., Fierro, M.T., Osella-Abate, S., and Bernengo, M.G. (2004). Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res. 14, S17-S19.
74. Ranieri, J.M., Wagner, J.D., Wiebke, E.A., Azuaje, R., Smith, M.L., Wenck, S., Daggy, J., and Coleman, J.J., III, (2005). Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast. Reconstr. Surg. 115, 1058-1063.
75. Reynolds, S.R., Albrecht, J., Shapiro, R.L., Roses, D.F., Harris, M.N., Conrad, A., Zeleniuch-Jacquotte, A., and Bystryn, J.-C. (2003). Changes in the presence of multiole markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. 9, 1497-1502.
76. Reynolds, S.R., Vergilis, I.J., Szarek, M., Ferrone, S., and Bystryn, J.C. (2006). Cytoplasmic melanoma-associated antigen (Cyt-Maa) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int. J. Cancer 119 157-161.
77. Richardson, D.R. (2000). The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. Eur. J. Biochem. 267, 1290-1298.
78. Samija, I., Lukac, J., Maric-Brozic, J., and Kusic, Z. (2004). Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croat Med. J. 45, 142-148.
79. Santonocito, C., Concolino, P., Lavieri, M.M. et al. (2005). Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100b, ldh, Nse biochemical markers. Clin. Chim. Acta 362, 85-93.
80. Sarantou, T., Chi, D.D., Garrison, D.A., Conrad, A.J., Schmid, P., Morton, D.L., and Hoon, D.S. (1997). Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 57, 1371-1376.
81. Schittek, B., Bodingbauer, Y., Ellwanger, U., Blaheta, H.J., and Garbe, C. (1999). Amplification of melana messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br. J. Dermatol. 141, 30-36.
82. Schmidt, H., Sorensen, B.S., Fode, K., Nexo, E., and der Maase, H. (2005). Tyrosinase messenger rna in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 15, 409-416.
83. Schmidt, H., Johansen, J.S., Gehl, J., Geertsen, P.F., Fode, K., and der Maase, H. (2006a). Elevated serum level of ykl-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106, 1130-1139.
84. Schmidt, H., Sorensen, B.S., Sjoegren, P., Christensen, I.J., Fode, K., Larsen, J., Nexo, E., and von der Maase, H. (2006b). Circulating tyrosinase and Mart-1mRNA does not independently predict relapse or survival in patients with AJCC stage i-ii melanoma. J. Invest. Dermatol. 126, 849-854.
85. Schrader, A.J., Probst-Kepper, M., Grosse, J., Kunter, U., Schenk, F., Franzke, A., Atzpodien, J., and Buer, J. (2000). Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 10, 355-362.
86. Seykora, J.T., Jih, D., Elenitsas, R., Horng, W.H., and Elder, D.E. (2003). Gene expression profiling of melanocytic lesions. Am. J. Dermatopathol. 25, 6-11.
87. Sheffield, M.V., Yee, H., Dorvault, C.C., Weilbaecher, K.N., Eltoum, I.A., Siegal, G.P., Fisher, D.E., and Chhieng, D.C. (2002). Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am. J. Clin. Pathol. 118, 930-936.
88. Shinozaki, M., Fujimoto, A., Morton, D.L., and Hoon, D.S. (2004). Incidence of B-raf oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 10, 1753-1757.
89. Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., and Blair, G.E. (1991). Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338, 1227-1229.
90. Steingrimsson, E., Copeland, N.G., and Jenkins, N.A. (2004). Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38, 365-411.
91. Strohal, R., Mosser, R., Kittler, H., Wolff, K., Jansen, B., Brna, C., Stingl, G., and Pehamberger, H. (2001). Mart-1/melan-a and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression. Melanoma Res. 11, 543-548.
92. Sugita, Y., Fujiwara, Y., Hoon, D.S., Miyamoto, A., Sakon, M., Kuo, C.T., and Monden, M. (2002). Overexpression of beta 1,4n-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers. Oncology 62, 149-156.
93. Szenajch, J., Jasinski, B., Synowiec, A. et al. (2003). Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin. Chem. 49, 1450-1457.
94. Takeuchi, H., Morton, D.L., Kuo, C., Turner, R.R., Elashoff, D., Elashoff, R., Taback, B., Fujimoto, A., and Hoon, D.S.B. (2004). Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J. Clin. Oncol. 22, 2671-2680.
95. Talantov, D., Mazumder, A., Yu, J.X., Briggs, T., Jiang, Y., Backus, J., Atkins, D., and Wang, Y. (2005). Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234-7242.
96. Theos, A.C., Truschel, S.T., Raposo, G., and Marks, M.S. (2005). The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 18, 322-336.
97. Torabian, S., and Kashani-Sabet, M. (2005). Biomarkers for melanoma. Curr. Opin. Oncol. 17, 167-171.
98. Tsao, H., Nadiminti, U., Sober, A.J., and Bigby, M. (2001). A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol. 137, 325-330.
99. Ueda, Y., and Richmond, A. (2006). NF-κ B activation in melanoma. Pigment Cell Res. 19, 112-124.
100. Ulmer, A., Schmidt-Kittler, O., Fischer, J., Ellwanger, U., Rassner, G., Riethmuller, G., Fierlbeck, G., and Klein, C.A. (2004). Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 10, 531-537.
101. Vergilis, I.J., Szarek, M., Ferrone, S., and Reynolds, S.R. (2005). Presence and prognostic significance of melanoma-associated antigens Cyt-Maa and Hmw-Maa in serum of patients with melanoma. J. Invest. Dermatol. 125, 526-531.
102. Voit, C., Kron, M., Rademaker, J., Schwurzer-Voit, M., Sterry, W., Weber, L., Ozdemir, C., Proebstle, T., and Keilholz, U. (2005). Molecular staging in stage ii and iii melanoma patients and its effect on long-term survival. J. Clin. Oncol. 23, 1218-1227.
103. de Vries, T.J., Smeets, M., de Graaf, R., Hou-Jensen, K., Brocker, E.B., Renard, N., Eggermont, A.M., van Muijen, G.N., and Ruiter, D.J. (2001). Expression of gp100, Mart-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC melanoma cooperative group. J. Pathol. 193, 13-20.
104. Wascher, R.A., Morton, D.L., Kuo, C., Elashoff, R.M., Wang, H.J., Gerami, M., and Hoon, D.S. (2003). Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 21, 2558-2563.